With an emphasis on emerging biotechnology and biopharmaceutical companies, Robin M. Silva manages and counsels clients in domestic and international issues, focusing on IP portfolio strategic development. Her background includes patent prosecution, IP due diligence (opinions, financings, evaluating IP portfolios in connection with due diligence for acquisitions, mergers, financings, collaborations, and partnering deals), global portfolio management and mining, technical litigation support, and working with business development personnel and licensing managers to maximize portfolio value.
Robin represents start-ups, emerging and public companies, and other biotechnology clients in her IP practice. Her 20 years of experience in biochemistry includes antibodies and biologics, nucleic acid applications (including clinical and molecular diagnostics, “lab on a chip,” sequencing, synthesis, and RNAi), industrial enzymes and bioprocesses, animal and plant transgenics, and viruses and vaccines. She is also active in the emerging immuno-oncology area, including IO antibodies and combination therapies including PD-1, CTLA-4 and GITR IO constructs, amongst others.
In particular, Robin has implemented patent strategies for a number of therapeutic antibodies from inception into clinical trials as well as done all the patent work for a number of university start-ups through IPOs.
She was previously a patent partner and co-chair of the life sciences group of another international law firm, and currently co-chairs Morgan Lewis’s IP Business Development Committee. Prior to law school, Robin worked in the protein chemistry department at Genencor. She holds a B.S. in molecular, cellular, and developmental biology and has authored 12 peer-reviewed journal articles.
University of California, Berkeley School of Law (Boalt Hall), 1993, J.D.